Send us Feedback

Elan Corporation (ELN)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

ELN » Topics » Biopharmaceuticals

This excerpt taken from the ELN 6-K filed Mar 30, 2009.
Biopharmaceuticals
 
                                         
                      Adjusted
 		       
                      Comparative
 		       
    IFRS
 		    IFRS
 		          Basis
 		       
    2008
 		    2007
 		    Adjustments
 		    2007
 		    % increase/
 		 
    $m     $m     $m     $m     (decrease)  
 
 
Product revenue
    462.6       222.9       85.7       308.6       50 %
Contract revenue
    —       7.3       —       7.3       (100 )%
                                         
Total revenue
    462.6       230.2       85.7       315.9       46 %
Cost of sales
    173.4       69.1       55.2       124.3       40 %
                                         
Gross profit
    289.2       161.1       30.5       191.6       51 %
Selling, general and administrative expenses
    237.9       553.2       30.5       583.7       (59 )%
Research and development expenses
    286.8       223.3       —       223.3       28 %
                                         
Operating loss
    (235.5 )     (615.4 )     —       (615.4 )     (62 )%
 
This excerpt taken from the ELN 6-K filed Mar 31, 2008.
Biopharmaceuticals
 
                   
    2007
 		  2006
 		  % increase/
    $m   $m   (decrease)
 
Product revenue
    222.9     252.3     (12)%
Contract revenue
    7.3     —     —
                   
Total revenue
    230.2     252.3     (9)%
Cost of sales
    69.1     67.6     2%
                   
Gross profit
    161.1     184.7     (13)%
Selling, general and administrative expenses
    553.2     377.0     47%
Research and development expenses
    223.3     180.1     24%
Net gain on divestment of product
    —     (7.4)     (100%)
                   
Operating loss
    (615.4)     (365.0)     69%
                   
 

EXCERPTS ON THIS PAGE:

6-K
Mar 30, 2009
6-K
Mar 31, 2008

RELATED TOPICS for ELN:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki